Free shipping on all orders over $ 500

Capmatinib (INCB28060)

Cat. No. M2080
Capmatinib (INCB28060) Structure
Synonym:

INC280; Capmatinib; NVP-INC280

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 28  USD28 In stock
5mg USD 49  USD49 In stock
10mg USD 68  USD68 In stock
25mg USD 98  USD98 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Capmatinib (INCB28060) is a potent, orally available selective inhibitor of the c-MET receptor tyrosine kinase, a clinically validated cancer target. Capmatinib (INCB28060) exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. INCB28060 potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. Capmatinib (INCB28060) potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro. Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and INCB28060 is well tolerated at doses that achieve complete tumor inhibition.

Product Citations
Customer Product Validations & Biological Datas
Source Mol Cancer Ther (2017). Figure 4. INCB28060 (Abmole Bioscience. Houston, TX, USA)
Method oral gavage
Cell Lines KPC and orthotopic transplant model mice
Concentrations 1 mg/kg
Incubation Time 7, 14 or 21 days
Results Importantly, the group with dual inhibitor treatment in addition to gemcitabine showed no metastases. This result suggests that the combination of c-Met and Hh inhibitors in addition to gemcitabine has significantly suppressed metastasis formation.
Source Mol Cancer Ther (2017). Figure 3. INCB28060 (Abmole Bioscience. Houston, TX, USA)
Method oral gavage
Cell Lines KPC and orthotopic transplant model mice
Concentrations 1 mg/kg
Incubation Time 7, 14 or 21 days
Results These results suggest that the resistance to the c-Met and Hh inhibitor is developed following a prolonged treatment of each individual inhibitor; however, the resistance may be overcome by combining both c-Met and Hh inhibitors.
Source Mol Cancer Ther (2017). Figure 1. INCB28060 (Abmole Bioscience. Houston, TX, USA)
Method oral gavage
Cell Lines KPC and orthotopic transplant model mice
Concentrations 1 mg/kg
Incubation Time 7, 14 or 21 days
Results The data suggest that combination of both inhibitors with gemcitabine shows a trend in shrinkage of primary tumor volume in both mouse models of PDA after one week of treatment regimen.
Source Can Res (2017). Figure 3.INC280 (Abmole Bioscience).
Method
Cell Lines PDAC cells
Concentrations
Incubation Time
Results As expected, neither the Hh inhibitor nor the HGF/c-Met inhibitor affected the levels of total AnxA2 or P-Y23-AnxA2 in Panc10.05 cells in the singly cultured serum-reduced media (Fig. 3A and B; Supplementary Fig. S5E and S5F). It is likely the concentration of HGFand IGF-1 in serum-reduced media is lower than the effective thresholds.
Source Nature (2015). Figure 3. PF-04217903 and INCB28060 (AbMole Bioscience)
Method mice treatment in vivo and histological evaluation
Cell Lines B16F10 cells
Concentrations 40mg/kg PF-04217903 and 50mg/kg INCB28060
Incubation Time 2 weeks
Results Systemic treatment of WT mice carrying B16F10 melanomas (which are dependent on MET14) with three different MET tyrosine-kinase inhibitors (PF-04217903, INCB28060 and JNJ-38877605), strongly reduced TAN recruitment .
Source Nature (2015). Figure 2. PF-04217903 and INCB28060 (AbMole Bioscience)
Method mice treatment in vivo and histological evaluation
Cell Lines B16F10 cells
Concentrations 40mg/kg PF-04217903
Incubation Time 2 weeks
Results "Systemic administration of PF-04217903 decreased the weight and volume of B16F10 melanomas by 36% and 54%, respectively. Instead, MET knockdown in cancer cells only, led to 58% and 75% inhibition of tumour growth and volume.TAN inhibition by PF-04217903 was comparable in both Met-silenced and scrambled B16F10 melanomas."
Protocol (for reference only)
Cell Experiment
Cell lines SUN-5 and SUN-1 cells
Preparation method Optimal cell density used in the viability assay was predetermined for individual cell lines. To determine compound potency, cells were seeded into 96-well microplates at the appropriate density in media containing 1% to 2% FBS and supplemented with serial dilutions of INCB28060 in a final volume of 100 μL per well. After 72-hour incubation, 24 μL of CellTiter 96 AQueous One Solution (Promega) was added to each well, and the plates were incubated for 2 hours in a 37°C incubator. The optical density was measured in the linear range using a microplate reader at 490 nm with wavelength correction at 650 nm. IC50 values were calculated using the GraphPad Prism Software.
Concentrations 0~333 nM
Incubation time 3 days
Animal Experiment
Animal models B16F10 tumour-bearing mice
Formulation 0.5% methylcellulose in saline
Dosages 50mg/kg INCB28060
Administration via oral gavage every day once a day starting from day 2 after tumour injection and twice a day from day 11 until the end of the experiment(2 weeks)
Chemical Information
Molecular Weight 412.42
Formula C23H17FN6O
CAS Number 1029712-80-8
Solubility (25°C) DMSO 15 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Sung-Hwa Sohn, et al. BMC Res Notes. INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification

[2] Sabrina Baltschukat, et al. Clin Cancer Res. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

[3] Liu X, et al. Clin Cancer Res. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

Related c-Met Products
Caveolin-1 (82-101) amide (human, mouse, rat)

Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs.

Norleual

Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM.

Fosgonimeton

Fosgonimeton is a potentially first-in-class Hepatocyte Growth Factor Receptor (HGF) agonist that enhances HGF/MET signaling pathway activity for Alzheimer's Disease (AD) research.

SU 5616

SU 5616 is an organic compound.

MET/PDGFRA-IN-2

MET/PDGFRA-IN-2 is a MET and PDGFRA protein inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Capmatinib (INCB28060), INC280; Capmatinib; NVP-INC280 supplier, c-Met, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.